Cao YX, et al. - Physicians performed this meta-analysis to explore the effect of 2 clinically applied proprotein convertase subtilisin/kexin type 9 monoclonal antibody (PCSK9-mAb) on glycaemia and new-onset diabetes mellitus (NODM). Despite PCSK9-mAb types, participant characteristics, treatment duration, treatment method and differences of control treatment, Alirocumab and Evolocumab (2 kinds of PCSK9-mAb approved by FDA and EMA) had no significant impact on NODM and glucose homeostasis. They found no effect of baseline age, body mass index, male rate, treatment duration, and percent change of LDL-C on diabetes risks.